CompletedNot Applicable

Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass

Spain116 participantsStarted 2018-08-15

Plain-language summary

Haemo-autologous Antegrade Repriming (HAR) is a procedure based in the combination of evidence proven measures designed to reduce the haemodilution caused by establishing the cardiopulmonary bypass (CPB) during cardiac surgery. This clinical trial aims to determinate, in one hand, the benefits related to HAR in terms of transfusion, ICU stay, ventilation time, early mortality and complications. In the other hand analyzes the gaseous microemboli (GME) load, comparing the oxygenators venting technology´s efficiency in treatment and control group, and its relation with patient´s neurocognitive status.

Who can participate

Age range50 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- All patients purposed to undergo elective cardiopulmonary bypass for cardiac valve surgery or other pathologies requiring to open heart chambers. Exclusion Criteria: * Urgency and emergency * Heart transplantations * Severe cognitive affection * Active sepsis * Previous anemia * Early re-intervention * Pre-Op extracorporeal membrane oxygenation (ECMO) support * Hemodynamic unstability during HAR * Any clinical condition that may force protocol deviation

What they're measuring

Transfusion

Timeframe: 1 year

ICU stay

Timeframe: 1 year

Ventilation time

Timeframe: 1 year

Complications

Timeframe: 1 year

Mortality

Timeframe: 1 year

Trial details

NCT IDNCT03720184

SponsorJuan Blanco Morillo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-09-01

View on ClinicalTrials.gov More Anemia trials